56
Participants
Start Date
March 11, 2019
Primary Completion Date
December 20, 2019
Study Completion Date
December 20, 2019
Cypep-1
"Eligible subjects will be randomized to one of the two treatment groups in a ratio of 1:1 (active:placebo).~The treatment groups are:~* CyPep-1 topical formulation 1% (w/w)~* Vehicle topical formulation (placebo) The minimum set of studied warts is 1 treated common wart per subject. The subjects will be randomly assigned to treatment. During the treatment period topical formulation will be applied daily on to a maximum of 3 warts. One selected wart will serve as target wart, i.e. the primary wart, for detailed analysis. Selection of warts will be based on the feasibility to conduct treatment application and pharmacodynamics (including biopsy sampling) on the region of interest."
Centre for Human Drug Research, Leiden
Centre for Human Drug Research, Netherlands
OTHER